Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare Technologies Inc. (Nasdaq: GEHC) has announced a cash dividend for the third quarter of 2024. The company's Board of Directors has declared a dividend of $0.03 per share of Common Stock. This dividend will be payable on November 15, 2024 to all shareholders of record as of October 18, 2024. This announcement demonstrates GE HealthCare's commitment to providing regular returns to its shareholders, albeit at a modest level.
GE HealthCare Technologies Inc. (Nasdaq: GEHC) has priced its upsized secondary public offering of 15,000,000 shares of common stock at $86.00 per share. The offering was increased from the initially announced 10,000,000 shares. GE HealthCare will not receive any proceeds from the sale. Prior to closing, GE Aerospace is expected to exchange the shares for debt held by Morgan Stanley affiliates. The selling stockholder has granted underwriters an option to purchase an additional 2,250,000 shares. Morgan Stanley and Citigroup are leading the offering, which is expected to close on September 16, 2024, subject to customary conditions.
GE HealthCare Technologies Inc. (Nasdaq: GEHC) has announced a secondary public offering of 10,000,000 shares of its common stock. The company itself is not selling any shares or receiving proceeds from the sale. Prior to the offering's closing, GE Aerospace is expected to exchange the GEHC shares for debt held by Morgan Stanley affiliates. The selling stockholder has granted underwriters an option to purchase an additional 1,500,000 shares for settlement by September 30, 2024. Morgan Stanley and Citigroup are acting as lead joint book-running managers for the offering. The company has filed an automatically effective shelf registration statement with the SEC for this offering.
GE HealthCare (Nasdaq: GEHC) announced CE marks for two innovative cardiology solutions: the Vscan Air™ SL with Caption AI™, an AI-driven handheld ultrasound system for rapid cardiac assessments, and ECG-less Cardiac CT scanning on its Revolution Apex™ platform. These technologies aim to enable more efficient and timely cardiac care at the point of service.
The Vscan Air SL with Caption AI provides real-time guidance for capturing cardiac images, even for non-experts, and includes an AutoEF feature for calculating left ventricular ejection fraction. The ECG-less Cardiac CT solution allows for cardiac imaging without an ECG signal, prioritizing patient access and speed.
Both innovations will be showcased at the European Society of Cardiology (ESC) Congress in London, August 30-September 2, 2024, along with GE HealthCare's Allia™ IGS 5 Pulse image-guided platform for interventional cardiology.
GE HealthCare (Nasdaq: GEHC) has announced its management's participation in two upcoming investor conferences in September 2024. The company will be presenting at the 2024 Wells Fargo Healthcare Conference in Boston on September 4 at 10:15 am ET, and the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 5 at 1:05 pm ET.
Investors and interested parties can access these presentations through the GE HealthCare Investor Relations website. This announcement highlights the company's commitment to engaging with investors and sharing insights about its operations and future prospects in the healthcare industry.
GE HealthCare (Nasdaq: GEHC) announced the publication of the MASTER trial results in Anesthesia and Analgesia, demonstrating the safety and efficacy of End-tidal Control software for inhaled anesthetic administration. The study, conducted across four U.S. hospitals with 210 adult patients, showed that End-tidal Control achieved:
- Targeted end-tidal anesthetic concentrations within 5% of the set value 98% of the time, compared to 46% with manual control
- Targeted end-tidal oxygen concentrations within 5% of the set value 86% of the time, versus 41% with manual control
- Faster response times for achieving 90% of the initial desired end-tidal anesthetic concentration (median 75 seconds vs. 158 seconds)
The software also demonstrated potential to reduce anesthetic agent usage, greenhouse gas emissions, and costs compared to manual control.
GE HealthCare has announced a collaboration with the University of California San Diego School of Medicine to develop advanced MRI protocols and educational materials for women's pelvic imaging. The project, led by Dr. Rebecca Rakow-Penner, aims to improve diagnosis and management of female pelvic diseases such as endometriosis and ovarian cancer. This initiative addresses the gap in medical research and care for women's pelvic health, which is often understudied and misdiagnosed.
The collaboration seeks to democratize advanced imaging for women and increase access to high-quality care. By creating training materials and protocols, the project aims to equip clinicians worldwide with tools to deliver better care. This could potentially improve patient experiences and help clinicians make more informed decisions, ultimately bridging an important gap in women's healthcare.
GE HealthCare (GEHC) reported its Q2 2024 financial results, with flat revenues at $4.8 billion year-over-year and 1% organic revenue growth. The net income margin increased slightly to 8.9% from 8.7%, and adjusted EBIT margin rose to 15.3% from 14.8%. Diluted EPS improved to $0.93 from $0.91, while adjusted EPS grew to $1.00 from $0.92. However, the company experienced a decline in cash flow from operating activities to $(119) million from $(67) million and free cash flow to $(182) million from $(136) million.
Segment performance varied, with Imaging revenue down 1%, Ultrasound down 2%, Patient Care Solutions flat, and Pharmaceutical Diagnostics up 12%. GE HealthCare revised its full-year guidance, lowering organic revenue growth to 1-2% from approximately 4%, but raising adjusted EBIT margin to 15.7-16.0% from 15.6-15.9%.
CEO Peter Arduini highlighted strong orders growth in the U.S. and ongoing investments in future growth despite challenges in the China market. The company also announced several strategic collaborations and acquisitions to advance healthcare technologies.
GE HealthCare (GEHC) and Amazon Web Services (AWS) have announced a strategic collaboration to develop generative AI applications for healthcare. GE HealthCare has selected AWS as its strategic cloud provider to build and implement new foundation models aimed at transforming healthcare. The collaboration will utilize AWS services like Amazon Bedrock, Amazon Q Developer, and Amazon SageMaker to accelerate the development of medical technologies and streamline clinical workflows.
The partnership aims to improve diagnostic accuracy, enhance patient outcomes, and promote equitable care. GE HealthCare plans to leverage AWS's healthcare-specific cloud services and generative AI capabilities to build transformative clinical foundation models and applications, potentially reducing application development cycles from years to months.
GE HealthCare (Nasdaq: GEHC) has announced an agreement to acquire Intelligent Ultrasound Group's clinical AI software business for approximately $51 million. This acquisition aims to enhance GE HealthCare's ultrasound portfolio with AI-driven image analysis tools, improving workflow efficiency and ease-of-use for clinicians.
Key highlights include:
- Integration of Intelligent Ultrasound's ScanNav Assist AI technology into GE HealthCare's ultrasound systems
- Addition of R&D experts to drive AI-enabled innovation in Women's Health ultrasound devices
- Support for GE HealthCare's precision care strategy to address inefficiencies and improve patient care quality
The transaction is expected to close in Q4 2024, subject to customary closing conditions.